

**Brilliant Violet 750™ anti-human CD185 (CXCR5)**

**Catalog # /** 2384710 / 100 tests  
**Size:** 2384705 / 25 tests

**Clone:** J252D4

**Isotype:** Mouse IgG1, κ

**Immunogen:** Human CXCR5-transfected cells


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 750™ under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

**Workshop Number:** V CD08.10

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD19 FITC and CD185 (clone J252D4) Brilliant Violet 750™ (left) or mouse IgG1, κ Brilliant Violet 750™ isotype ctrl (right).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μL per million cells in 100 μL staining volume or 5 μL per 100 μL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 750™ excites at 405 nm and emits at 750 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 750™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Clone HIT8a recognizes the alpha chain of CD8<sup>5</sup>. It does not block the binding of RPA-T8 antibody to CD8a.

Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>5,6</sup>. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue.

**Application  
References:**

1. Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, *et al.* 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Awasthi, S., *et al.* 2011. *J. Virol* 85:10472. [PubMed](#)
  5. Coppieters KT, *et al.* 2012. *J. Exp. Med.* 209:51. (IHC, epitope)
  6. Suzuki F, *et al.* 2012. *Arthritis Res. Ther.* 14:R48. (IHC)
- 

**Description:** CD185, also known as CXCR5, is a 42 kD G-protein coupled receptor with seven transmembrane regions. CXCR5 is expressed by mature B cells, follicular helper T cells, Burkitt's lymphoma cells and a subset of neurons, and mediates cell migration to the B cell follicles in the secondary lymphoid organs. The ligand of CXCR5 is CXCL13 (BLC).

**Antigen  
References:**

1. Ma CS, *et al.* 2012. *J. Exp. Med.* 209:1241.
2. Leon B, *et al.* 2012. *Nat. Immunol.* 13:681.
3. Crotty S. 2011. *Annu. Rev. Immunol.* 29:621.
4. Kerfoot SM, *et al.* 2011. *Immunity* 34:947.
5. Sáez de Guinoa J, *et al.* 2011. *Blood* 118:1560.